Abstract Number: 2841 • 2018 ACR/ARHP Annual Meeting
Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in a global, phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with Behçet’s syndrome and…Abstract Number: 431 • 2017 ACR/ARHP Annual Meeting
Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis: An Interim Report of Safety Data
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib have been shown in patients…Abstract Number: 806 • 2017 ACR/ARHP Annual Meeting
Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database
Background/Purpose: The giant cell arteritis (GCA) management requires the administration of high-dose glucocorticoid (GC) at the introduction remission and the gradual reduction of the dosage.…Abstract Number: 1165 • 2017 ACR/ARHP Annual Meeting
Clinical Characteristics of Patients with Late-Onset Familial Mediterranean Fever in Japan
Background/Purpose: Familial Mediterranean fever (FMF) is an auto-inflammatory disease characterized by recurrent episodes of fever and polyserositis. Most patients have their first febrile attack before…Abstract Number: 1343 • 2017 ACR/ARHP Annual Meeting
Gingival Bleeding and Periodontitis in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Background/Purpose: Oral health is an important issue for patients with rheumatoid arthritis (RA) because periodontitis is a potential risk factor for RA and RA patients…Abstract Number: 2588 • 2017 ACR/ARHP Annual Meeting
Early Exposure to Hydroxychloroquine Predicts Good Renal Response in Japanese Patients with Lupus Nephritis Class III or IV
Background/Purpose: The guideline or recommendation for lupus nephritis (LN) has been recently established by both ACR and EULAR, and hydroxychloriquine (HCQ) is recommended for all…Abstract Number: 331 • 2016 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Anti-Rheumatic Drug Use and the Risk of Non-Vertebral Osteoporotic Fractures in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Background/Purpose: Previous U.S. and Canadian studies [1-3] have suggested that no significant associations exist between use of biologic disease-modifying anti-rheumatic drugs (DMARDs) and risk of…Abstract Number: 608 • 2016 ACR/ARHP Annual Meeting
Initial Intensive Therapy of Adalimumab and Methotrexate Is Associated with Long-Term Structural Remission and Low Disease Activity after Adalimumab Discontinuation Is Maintained up to 3 Years in Japanese Patients: Hopeful-3 Study
Background/Purpose: Methods: Of 172 patients enrolled, 135 (ADA continuation, n=61; ADA discontinuation, n=74) with DAS28–CRP at both week 52 (start of HOPEFUL-2) and week 208…Abstract Number: 609 • 2016 ACR/ARHP Annual Meeting
Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the Anouveau Study (Clinicaltrial.gov: NCT01346488)
Background/Purpose: Patients with Rheumatoid Arthritis (RA) experience loss of productivity such as missing their work and lowering their performance incurred by impaired physical functioning. Treatment…Abstract Number: 1598 • 2016 ACR/ARHP Annual Meeting
Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes
Background/Purpose: Rheumatoid arthritis (RA) has a high patient (pt) burden with significant impact on health-related quality of life. We report the effect of treatment with…Abstract Number: 344 • 2015 ACR/ARHP Annual Meeting
Results of a Phase 2 Clinical Trial to Evaluate the Effects of Romosozumab in Japanese Women with Postmenopausal Osteoporosis
Background/Purpose: Romosozumab is a sclerostin inhibitor that rapidly increases bone mineral density (BMD) through a dual effect on bone, causing increased bone formation and decreased…Abstract Number: 349 • 2015 ACR/ARHP Annual Meeting
Comparison Between the American Recommendations and the Japanese Guidelines for Glucocorticoid-Induced Osteoporosis in Japanese Patients with Rheumatoid Arthritis
Background/Purpose: In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) updated their guidelines for the management and treatment of glucocorticoid-induced osteoporosis (GIO) and…Abstract Number: 384 • 2015 ACR/ARHP Annual Meeting
Dental Treatments, Tooth Extraction, and Osteonecrosis at Jaw in Japanese Patients with Rheumatoid Arthritis; Results from the IORRA Cohort Study
Background/Purpose: Oral health is an important issue for the patients with rheumatoid arthritis (RA) because many RA patients were treated with bisphosphonates and bisphosphate use…Abstract Number: 2470 • 2014 ACR/ARHP Annual Meeting
Treatment Strategy for Maximizating the Effect of Adalimumab in Japanese Patients with Rheumatoid Arthritis : Retrospective Analyses of Data Collected from the Patient Treated with Adalimumab in Routine Clinical Practice in Hamamatsu Area
Background/Purpose: Adalimumab (ADA) showed highly efficacious in rheumatoid arthritis (RA) in the clinical trials, although there is little evidence in daily clinical practice.The clinical usefulness…Abstract Number: 2418 • 2014 ACR/ARHP Annual Meeting
Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data
Background/Purpose Biologics such as etanercept (ETN), adalimumab (ADA), infliximab (IFX) and tocilizumab (TCZ) have led dramatic improvement in the treatment of rheumatoid arthritis (RA), but…